What it is
Dulaglutide is a GLP-1 drug built on an antibody chassis. Most GLP-1 medicines in this library are single peptides — liraglutide and semaglutide are 31 amino acids each, stretched to a daily or weekly schedule by a fatty-acid chain. Dulaglutide took a different route:
- Two identical chains, linked by disulfide bonds;
- each chain begins with a GLP-1 analogue that is 90% identical to human GLP-1 (7-37);
- a short peptide linker joins that analogue to the Fc portion of a modified human IgG4 antibody.
The result weighs about 63 kilodaltons, according to the Trulicity label. Semaglutide weighs 4,113.6. So dulaglutide is roughly 15 times heavier than the drug most readers compare it with, and it is made in Chinese hamster ovary cells rather than by chemical synthesis. Strictly, that makes it a fusion protein carrying a peptide, not a peptide — which is why it sits here as a GLP-1 medicine rather than beside the short research peptides.
How it works
The GLP-1 end of the molecule does the work. Per the label, dulaglutide activates the GLP-1 receptor on pancreatic beta cells, which raises insulin release only when glucose is high, lowers glucagon and slows stomach emptying. The antibody end does the timing: Fc fragments are recycled by the body instead of filtered out, which is why the label reports an elimination half-life of about 5 days — longer than any single-peptide GLP-1 drug in this library except those carrying a fatty-acid chain.
The label also records how much reaches the blood from an injection under the skin: 65% at 0.75 mg and 47% at 1.5 mg. Peak levels arrive a median 48 hours after a dose.
What it is approved for
| Use | Source |
|---|---|
| Blood-sugar control in type 2 diabetes, adults and children 10+ | Trulicity label, indication 1 |
| Reducing heart attack, stroke and cardiovascular death in adults with type 2 diabetes and heart disease or multiple risk factors | Trulicity label, indication 2 (from REWIND) |
Stated limits on the same label: not for type 1 diabetes; not studied in people with a history of pancreatitis; not recommended in severe gastrointestinal disease, including severe gastroparesis. There is no weight-management indication. Weight change appears in its trials only as a secondary finding.
The heart trial
REWIND is what separates dulaglutide from several other GLP-1 drugs. It was published in The Lancet in 2019 (NCT01394952):
| Measure | Dulaglutide 1.5 mg | Placebo |
|---|---|---|
| Participants | 4,949 | 4,952 |
| Median follow-up | 5.4 years | 5.4 years |
| Heart attack, stroke or cardiovascular death | 594 (12.0%) | 663 (13.4%) |
| Hazard ratio (95% CI) | 0.88 (0.79–0.99) | — |
| All-cause death | 10.8% | 12.0% (not significant) |
Two features made it unusual: participants were older (mean age 66), and many had no prior heart event — only risk factors. The median HbA1c at entry was 7.2%, lower than in most outcome trials.
Doses on the label
Reported as the label states them, not as guidance: the adult label runs from 0.75 mg once weekly through 1.5, 3 and 4.5 mg, stepping up in 1.5 mg increments no sooner than every four weeks. The paediatric maximum is 1.5 mg. A missed dose is given only if at least 72 hours remain before the next one.
Safety
The label carries a boxed warning for thyroid C-cell tumours: dulaglutide caused them in rats, and "it is unknown" whether it does so in humans. It is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Other warnings: pancreatitis, low blood sugar when combined with insulin or sulfonylureas, acute kidney injury from fluid loss, severe gut disease, complications in people with existing diabetic retinopathy, and gallbladder disease. The most common side effects (5% or more) are nausea, diarrhoea, vomiting, abdominal pain and reduced appetite.
Where it stands
FDA application data list one application — Lilly's BLA125469, approved 18 September 2014 — with four strengths and no generic or biosimilar on 2026-09-27. ClinicalTrials.gov holds 142 records with dulaglutide as an intervention. Europe PMC's MEDLINE index holds 1,215 records naming it in the title or abstract, 141 tagged as randomised controlled trials.
Related reading
Dulaglutide's closest relatives here are liraglutide, the daily GLP-1 peptide, and tirzepatide, which adds a second receptor. Exenatide, the first drug of the class, came from lizard venom rather than the human hormone. For the practical and cost questions around GLP-1 treatment, GLP1 Ledger covers them in its GLP-1 guides.